Total Payments
$30,753
2023 Payments
$11,279
Companies
9
Transactions
47
Medicare Patients
407
Medicare Billing
$141,442
Payment Breakdown by Category
Consulting$14,250 (46.3%)
Travel$10,606 (34.5%)
Research$3,083 (10.0%)
Other$2,098 (6.8%)
Food & Beverage$715.89 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $14,250 | 4 | 46.3% |
| Travel and Lodging | $10,606 | 19 | 34.5% |
| Unspecified | $3,083 | 2 | 10.0% |
| Honoraria | $2,055 | 1 | 6.7% |
| Food and Beverage | $715.89 | 20 | 2.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $43.36 | 1 | 0.1% |
Payments by Type
General
$27,670
45 transactions
Research
$3,083
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $8,720 | 14 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $5,584 | 11 | $0 (2017) |
| PFIZER INC. | $5,372 | 4 | $0 (2017) |
| Jazz Pharmaceuticals Inc. | $4,779 | 6 | $0 (2017) |
| Celgene Corporation | $3,127 | 4 | $0 (2019) |
| Rigel Pharmaceuticals, Inc. | $3,088 | 5 | $0 (2023) |
| Servier Pharmaceuticals LLC | $43.36 | 1 | $0 (2021) |
| Astellas Pharma US Inc | $20.98 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $18.70 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $11,279 | 13 | AbbVie Inc. ($8,191) |
| 2021 | $64.34 | 2 | Servier Pharmaceuticals LLC ($43.36) |
| 2019 | $1,620 | 1 | Celgene Corporation ($1,620) |
| 2017 | $17,790 | 31 | Millennium Pharmaceuticals, Inc. ($5,584) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $2,055.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/01/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| 12/01/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $64.91 | General |
| 11/11/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $602.80 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/11/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $330.48 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/11/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/11/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/07/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $1,024.82 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $47.82 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $47.82 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2021 | Astellas Pharma US Inc | XOSPATA (Drug) | Food and Beverage | In-kind items and services | $20.98 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2021 | Servier Pharmaceuticals LLC | TIBSOVO (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | In-kind items and services | $43.36 | General |
| Category: ONCOLOGY | ||||||
| 01/29/2019 | Celgene Corporation | Idhifa (Drug) | — | In-kind items and services | $1,620.00 | Research |
| Study: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (AG-221-C-001) • Category: Hematology | ||||||
| 12/14/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 12/07/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 12/07/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $354.53 | General |
| Category: Oncology | ||||||
| 12/07/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $344.40 | General |
| Category: Oncology | ||||||
| 12/07/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 12/07/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: Oncology | ||||||
| 11/07/2017 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug), TASIGNA | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: HEMATOLOGY | ||||||
| 10/27/2017 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $23.79 | General |
| 10/02/2017 | AbbVie, Inc. | — | Travel and Lodging | In-kind items and services | $74.75 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation (AG-221-C-001) | Celgene Corporation | $1,620 | 1 |
| AG-221-C-001 | Celgene Corporation | $1,463 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 155 | 423 | $164,617 | $45,126 |
| 2022 | 3 | 110 | 404 | $138,497 | $42,412 |
| 2021 | 4 | 122 | 476 | $146,115 | $50,366 |
| 2020 | 1 | 20 | 38 | $11,096 | $3,539 |
Total Patients
407
Total Services
1,341
Medicare Billing
$141,442
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 79 | 276 | $114,396 | $30,312 | 26.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 79 | $22,164 | $7,496 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $10,809 | $3,024 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 25 | $10,442 | $2,745 | 26.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 16 | 22 | $6,806 | $1,550 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 65 | 246 | $94,237 | $28,440 | 30.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 138 | $34,776 | $11,108 | 31.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $9,484 | $2,863 | 30.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 58 | 271 | $89,257 | $31,867 | 35.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 28 | 163 | $40,834 | $13,499 | 33.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $10,459 | $3,454 | 33.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 13 | 19 | $5,565 | $1,545 | 27.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 20 | 38 | $11,096 | $3,539 | 31.9% |
About Dr. Ronan Swords, M.D
Dr. Ronan Swords, M.D is a Internal Medicine healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2009. The National Provider Identifier (NPI) number assigned to this provider is 1720216401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronan Swords, M.D has received a total of $30,753 in payments from pharmaceutical and medical device companies, with $11,279 received in 2023. These payments were reported across 47 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($14,250).
As a Medicare-enrolled provider, Swords has provided services to 407 Medicare beneficiaries, totaling 1,341 services with total Medicare billing of $141,442. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology
- Location Portland, OR
- Active Since 07/01/2009
- Last Updated 09/08/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1720216401
Products in Payments
- BOSULIF (Drug) $5,372
- VYXEOS (Drug) $4,779
- Rezlidhia (Drug) $3,088
- Idhifa (Drug) $3,083
- VENCLEXTA (Drug) $1,376
- TIBSOVO (Drug) $43.36
- XOSPATA (Drug) $20.98
- Revlimid (Drug) $20.54
- RYDAPT (Drug) $18.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Portland
Nananda Col, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Stephen Yau, M.d, M.D
Internal Medicine — Payments: $980,262
Internal Medicine $980,262
Ethan Korngold, Md, MD
Internal Medicine — Payments: $610,759
Internal Medicine $610,759
Dr. Firas Zahr, Md, MD
Internal Medicine — Payments: $543,624
Internal Medicine $543,624
Dr. Martin Moehlen, M.d, M.D
Internal Medicine — Payments: $318,908
Internal Medicine $318,908
Scott Chadderdon, Md, MD
Internal Medicine — Payments: $189,078
Internal Medicine $189,078